Eli Lilly, Taikang and Tencent are in line to exit the diabetes equipment maker, which has filed to go public in Hong Kong next week.

Itochu, Qualcomm, Hearst, Catholic Health Initiatives, TriZetto and IBM are all set to exit the health plan platform developer.

Mednax led the paediatric healthcare provider's series B round, pushing its overall funding past the $40m mark.

Corporate-backed cloud networking software provider Pluribus pushed its total funding to at least $110m while IAG has exited Hyper Anna in an acquisition by Alteryx.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Amgen, SoftBank and Alexandria Real Estate Equities helped the neurodegenerative disease drug developer publicly launch with $500m in funding.

Bayer, Pfizer and Ipsen-backed cancer therapeutics developer Pyxis Oncology priced its shares at the top of its range.

The dental technology developer’s proposed listing on the New York Stock Exchange would mark an exit for Henry Crown and Company.

The Ariad Pharmaceuticals-backed cancer therapeutics developer floated at the top of its range following $120m in venture funding.

Having priced its shares at the top of its range, UChicago spinout Pyxis Oncology suffered a drop on the first day of trading.